Preventing progression of cardiac hypertrophy and development of heart failure by paricalcitol therapy in rats

Cardiovascular Research

Volumn 91, Issue 4, 2011, Pages 632-639

  Bae, Soochan ^a   Yalamarti, Bhargavi ^a   Ke, Qingen ^a   Choudhury, Sangita ^a   Yu, Hyeon ^a,b   Karumanchi, S Ananth ^c   Kroeger, Paul ^d   Thadhani, Ravi ^e   Kang, Peter M ^a,b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b Chonbuk National University   (South Korea)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^d ABBOTT LABORATORIES   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

ACE inhibitor; BNP; Dahl rats; Fibrosis; Microarrays

Indexed keywords

ENALAPRIL; PARICALCITOL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOCHEMISTRY; BLOOD PRESSURE; CONTROLLED STUDY; DISEASE COURSE; ECHOCARDIOGRAPHY; GENE EXPRESSION; HEART FAILURE; HEART VENTRICLE HYPERTROPHY; HEMODYNAMICS; HISTOPATHOLOGY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; CALCIUM; CARDIOMEGALY; DISEASE PROGRESSION; ERGOCALCIFEROLS; GENE EXPRESSION PROFILING; HEART FAILURE; HEMODYNAMICS; MALE; PROTEIN KINASE C-ALPHA; RATS; RATS, SPRAGUE-DAWLEY;

EID: 80052017300     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvr133     Document Type: Article

References (37)

1. Holick MF. Vitamin D deficiency. N Engl J Med 2007;357:266-281.
2. Lee W, Kang PM. Vitamin D deficiency and cardiovascular disease: is there a role for vitamin D therapy in heart failure? Curr Opin Investig Drugs 2010;11:309-314.
3. Uysal S, Kalayci AG, Baysal K. Cardiac functions in children with vitamin D deficiency rickets. Pediatr Cardiol 1999;20:283-286. (Pubitemid 29279632)
4. Shane E, Mancini D, Aaronson K, Silverberg SJ, Seibel MJ, Addesso V et al. Bone mass, vitamin D deficiency, and hyperparathyroidism in congestive heart failure. Am J Med 1997;103:197-207. (Pubitemid 27413402)
5. Wang TJ, Pencina MJ, Booth SL, Jacques PF, Ingelsson E, Lanier K et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008;117:503-511.
6. US Renal Data Systems. Causes of death in ESRD. Am J Kidney Dis 1999;34:S87-94.
7. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998;32:S112-119. (Pubitemid 28527268)
8. Bodyak N, Ayus JC, Achinger S, Shivalingappa V, Ke Q, Chen YS et al. Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. Proc Natl Acad Sci USA 2007;104:16810-16815. (Pubitemid 350210947)
9. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003; 349:446-456. (Pubitemid 36910023)
10. Teng M, Wolf M, Ofsthun MN, Lazarus JM, Hernan MA, Camargo CA Jr. et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005;16:1115-1125. (Pubitemid 41710323)
11. Sharma JN, Fernandez PG, Kim BK, Idikio H, Triggle CR. Cardiac regression and blood pressure control in the Dahl rat treated with either enalapril maleate (MK 421, an angiotensin converting enzyme inhibitor) or hydrochlorothiazide. J Hypertens 1983; 1:251-256. (Pubitemid 14161949)
12. Kim-Mitsuyama S, Izumi Y, Izumiya Y, Yoshida K, Yoshiyama M, Iwao H. Additive beneficial effects of the combination of a calcium channel blocker and an angiotensin blocker on a hypertensive rat-heart failure model. Hypertens Res 2004;27:771-779. (Pubitemid 40045517)
13. Kang PM, Yue P, Liu Z, Tarnavski O, Bodyak N, Izumo S. Alterations in apoptosis regulatory factors during hypertrophy and heart failure. Am J Physiol Heart Circ Physiol 2004;287:H72-80. (Pubitemid 38802338)
14. Kong SW, Bodyak N, Yue P, Liu Z, Brown J, Izumo S et al. Genetic expression profiles during physiologic and pathologic cardiac hypertrophy and heart failure in rats. Physiol Genomics 2005;21:34-42. (Pubitemid 40898463)
15. Siu PM, Bae S, Bodyak N, Rigor DL, Kang PM. Response of caspase-independent apoptotic factors to high salt diet-induced heart failure. J Mol Cell Cardiol 2007;42:678-686. (Pubitemid 46349134)
16. Rigor DL, Bodyak N, Bae S, Choi JH, Zhang L, Ter-Ovanesyan D et al. Phosphoinositide 3-kinase Akt signaling pathway interacts with protein kinase Cbeta2 in the regulation of physiologic developmental hypertrophy and heart function. Am J Physiol Heart Circ Physiol 2009;296:H566-572.
17. Choudhury S, Bae S, Kumar SR, Ke Q, Yalamarti B, Choi JH et al. Role of AIF in cardiac apoptosis in hypertrophic cardiomyocytes from Dahl salt-sensitive rats. Cardiovasc Res 2010;85:28-37.
18. Han Y, Chen YS, Liu Z, Bodyak N, Rigor D, Bisping E et al. Overexpression of HAX-1 protects cardiac myocytes from apoptosis through caspase-9 inhibition. Circ Res 2006; 99:415-423. (Pubitemid 44253698)
19. Kang PM, Haunstetter A, Aoki H, Usheva A, Izumo S. Morphological and molecular characterization of adult cardiomyocyte apoptosis during hypoxia and reoxygenation. Circ Res 2000;87:118-125. (Pubitemid 30616907)
20. Jeong D, Cha H, Kim E, Kang M, Yang DK, Kim JM et al. PICOT inhibits cardiac hypertrophy and enhances ventricular function and cardiomyocyte contractility. Circ Res 2006;99:307-314. (Pubitemid 44174939)
21. Simpson RU, Hershey SH, Nibbelink KA. Characterization of heart size and blood pressure in the vitamin D receptor knockout mouse. J Steroid Biochem Mol Biol 2007;103:521-524. (Pubitemid 46420533)
22. Li Y, Spataro BC, Yang J, Dai C, Liu Y. 1,25-dihydroxyvitamin D inhibits renal interstitial myofibroblast activation by inducing hepatocyte growth factor expression. Kidney Int 2005;68:1500-1510. (Pubitemid 43173380)
23. Wright JW, Mizutani S, Harding JW. Pathways involved in the transition from hypertension to hypertrophy to heart failure. Treatment strategies. Heart Fail Rev 2008;13: 367-375.
24. Belin RJ, Sumandea MP, Allen EJ, Schoenfelt K, Wang H, Solaro RJ et al. Augmented protein kinase C-alpha-induced myofilament protein phosphorylation contributes to myofilament dysfunction in experimental congestive heart failure. Circ Res 2007;101: 195-204. (Pubitemid 47196587)
25. Bowman JC, Steinberg SF, Jiang T, Geenen DL, Fishman GI, Buttrick PM. Expression of protein kinase C beta in the heart causes hypertrophy in adult mice and sudden death in neonates. J Clin Invest 1997;100:2189-2195. (Pubitemid 27500140)
26. Braz JC, Gregory K, Pathak A, Zhao W, Sahin B, Klevitsky R et al. PKC-alpha regulates cardiac contractility and propensity toward heart failure. Nat Med 2004;10:248-254. (Pubitemid 38667614)
27. Wakasaki H, Koya D, Schoen FJ, Jirousek MR,Ways DK, Hoit BD et al. Targeted overexpression of protein kinase C beta2 isoform in myocardium causes cardiomyopathy. Proc Natl Acad Sci USA 1997;94:9320-9325. (Pubitemid 27357827)
28. Kong J, Kim GH, Wei M, Sun T, Li G, Liu SQ et al. Therapeutic effects of vitamin D analogs on cardiac hypertrophy in spontaneously hypertensive rats. Am J Pathol 2010; 177:622-631.
29. Wu J, Garami M, Cheng T, Gardner DG. 1,25(OH)2 vitamin D3, and retinoic acid antagonize endothelin-stimulated hypertrophy of neonatal rat cardiac myocytes. J Clin Invest 1996;97:1577-1588. (Pubitemid 26105467)
30. O'Connell TD, Berry JE, Jarvis AK, Somerman MJ, Simpson RU. 1,25-Dihydroxyvitamin D3 regulation of cardiac myocyte proliferation and hypertrophy. Am J Physiol 1997;272:H1751-1758.
31. O'Connell TD, Weishaar RE, Simpson RU. Regulation of myosin isozyme expression by vitamin D3 deficiency and 1,25-dihydroxyvitamin D3 in the rat heart. Endocrinology 1994;134:899-905. (Pubitemid 24057239)
32. Chen S, Glenn DJ, Ni W, Grigsby CL, Olsen K, Nishimoto M et al. Expression of the vitamin d receptor is increased in the hypertrophic heart. Hypertension 2008;52: 1106-1112.
33. Nibbelink KA, Tishkoff DX, Hershey SD, Rahman A, Simpson RU. 1,25(OH)(2)-vitamin D(3) actions on cell proliferation, size, gene expression, and receptor localization, in the HL-1 cardiac myocyte. J Steroid Biochem Mol Biol 2007; 103:533-537. (Pubitemid 46420534)
34. Chen S, Wu J, Hsieh JC, Whitfield GK, Jurutka PW, Haussler MR et al. Suppression of ANP gene transcription by liganded vitamin D receptor: involvement of specific receptor domains. Hypertension 1998;31:1338-1342. (Pubitemid 28248837)
35. Xiang W, Kong J, Chen S, Cao LP, Qiao G, Zheng W et al. Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systems. Am J Physiol Endocrinol Metab 2005;288:E125-132. (Pubitemid 40023798)
36. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002;110: 229-238. (Pubitemid 34787360)
37. Li YC. Vitamin D regulation of the renin-angiotensin system. J Cell Biochem 2003;88: 327-331. (Pubitemid 36119906)